The total sample drug sales in China's pharmaceutical industry declined by 3% YoY in October, a sharp drop from the 6.8% YoY growth in September, BofA Securities released a research report saying.

HANSOH PHARMA (03692.HK)  -0.260 (-0.690%)    Short selling $11.97M; Ratio 16.771%   achieved the highest YoY incline among its peers in October, at 8.6%, the report noted. Most of HANSOH PHARMA's key products recorded double-digit MoM growth in October, except for PEG-loxenatide. Therefore, the broker kept rating at Buy, with a target price of $45.

Related NewsCMBI Ratings, TPs on Pharmas (Table)
Several key products of HENGRUI PHARMA (01276.HK)  -0.150 (-0.210%)    Short selling $7.77M; Ratio 16.494%   faced pressure in October, the report stated. The total sample sales hiked by 2% YoY in October. Therefore, BofA Securities kept rating at Underperform, with a target price of RMB57.7 for HENGRUI PHARMA's A-shares.

SINO BIOPHARM (01177.HK)  -0.030 (-0.465%)    Short selling $75.00M; Ratio 34.189%   showed mixed performance in its product mix in October, the report added. Based on sales performance, the broker lowered its sales forecasts for some products affected by VBP starting in 2026, and reduced its 2026/ 2027 revenue forecasts by 0.2%/ 0.4% each.

Therefore, BofA Securities cut its target price from $9.4 to $8.3, and reiterated rating at Buy based on the massive licensing potential of its pipeline products.

Related NewsCMBI Recommends 3SBIO, Viewing Pharma Sector Pullback as Rebalancing of Industry Valuation & Performance
Moreover, as several key drug sales of CSPC PHARMA (01093.HK)  -0.110 (-1.239%)    Short selling $446.67M; Ratio 39.106%   remained sluggish in October, the broker kept rating at Underperform, with a target price of $7.2.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-12-24 12:25.)